Profile
Sean Brynjelsen is the President & Chief Executive Officer and a Director of Eton Pharmaceuticals, Inc., and is listed as a 10% owner in the company’s SEC filing dated January 14, 2026. Eton is a specialty pharmaceutical company focused on developing and commercializing therapies for rare diseases, including Alkindi Sprinkle, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The SEC filing notes that Brynjelsen had no reported purchases or sales in that filing cycle.
| Role | President & CEO, Director |
|---|
| Notability | 25/100 |
|---|
Board memberships
- Eton Pharmaceuticals, Inc.
Awards & honors
- Named President & CEO and Director of Eton Pharmaceuticals, Inc.
- Owning a 10% stake as disclosed in the SEC filing
- Overseeing leadership of a portfolio of rare-disease products including Alkindi, Carglumic Acid, Betaine Anhydrous, and Nitisinone
Frequently Asked Questions
Who is BRYNJELSEN SEAN?
Sean Brynjelsen is the President & Chief Executive Officer and a Director of Eton Pharmaceuticals, Inc., and is listed as a 10% owner in the company’s SEC filing dated January 14, 2026. Eton is a specialty pharmaceutical company focused on developing and commercializing therapies for rare diseases, including Alkindi Sprinkle, Carglumic Acid, Betaine Anhydrous, and Nitisinone. T…
How many SEC Form 4 filings has BRYNJELSEN SEAN submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has BRYNJELSEN SEAN been buying or selling stock?
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($3.83M) across all tracked filings.
Where can I see all of BRYNJELSEN SEAN's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.